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Key Points
• Individuals with MGUS
did not have a de-
creased BMD com-
pared with others in a
screened population.
• Individuals with MGUS
had an increased bone
volume at the hip and
lumbar spine compared
with others.
Previous studies have shown that individuals with monoclonal gammopathy of
undetermined signiﬁcance (MGUS) have an increased risk of fractures, although the
underlying mechanisms remain unknown. Our aimwas to analyze bonemineral density
(BMD), bone volume, and risk of fractures among individuals with MGUS. We performed a
screening using the Age, Gene/Environment Susceptibility (AGES)–Reykjavik Study cohort,
consisting of 5764 elderly individuals, identifying 300 individuals with MGUS, and 275 with
light-chain MGUS. Quantitative computerized tomography was performed in the lumbar
spine and hip to evaluate BMD and bone geometry. Analysis of variance and the Tukey
honest signiﬁcance test were used to compare the groups. Hospital records were used to
record fractures, with a mean follow-up of 6.9 years. Cox proportional hazard was used to
compare fracture risk. No difference was found in BMD between subjects with MGUS and
others in the spine (P5 .34) or in total hip (P5 .30). Individuals with MGUS had a signiﬁcant
increase in bone volume compared with others in the spine (P, .001) and total hip (P, .001).
Overall, the risk of fractureswas not signiﬁcantly increased in individuals withMGUS (hazard
ratio [HR], 1.19; 95% conﬁdence interval [CI], 0.94-1.50). Men with MGUS had a signiﬁcantly
increased fracture risk, compared with other men (HR, 1.46; 95% CI, 1.03-2.08). Our results
show that although individuals with MGUS do not have decreased BMD, bone volume is
increased, and MGUS men have a 50% increased fracture risk. These results indicate that
bone disease and fractures in MGUS differ from processes known from osteoporosis.
Introduction
Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition preceding multiple
myeloma (MM) and other lymphoproliferative disorders. Accordingly, light-chain MGUS (LC-MGUS) is a
precursor condition preceding light-chain MM.1 The prevalence of MGUS increases with age, and is
higher in men than in women.2 Patients with MM have a high incidence of bone disease, including
osteopenia, osteolytic lesions, and fractures, which can significantly increase morbidity and mortality
in patients with MM.3 We previously performed a population-based study of 5326 MGUS patients
diagnosed in Sweden, compared with 20 161 matched controls, and observed a 1.6-fold significantly
increased risk of any fracture at 10 years’ follow-up in MGUS patients. Furthermore, there was a
higher risk for axial (skull, vertebral/pelvis, and sternum/costae) compared with distal (arm and leg)
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fractures.4 Results from other published studies on fractures in
MGUS patients5-8 have shown 1.4- to 6.3-fold increased risk of
fractures in MGUS patients. Researchers have found a high
prevalence of MGUS in osteoporotic patients,9-12 which has led
some authors to suggest that protein electrophoresis should
always be performed as screening for MGUS (and MM) in patients
with osteoporosis and/or fractures.9,10,13 However, these studies
have been limited by lack of control population, and the scientific
rationale for these recommendations is scarce.
Fractures are a known result of age-related osteoporosis, and risk of
fractures is increased in individuals with decreased bone mineral
density (BMD).14 Traditionally, risk of fractures due to age-related
bone loss is assessed from BMD, which is measured by dual-energy
x-ray absorptiometry (DXA). Quantitative computerized tomography
(QCT) is often used in osteoporotic research, and is a technique
that has several advantages over DXA, including that cortical and
trabecular bone can be separated, and trabecular volumes can be
estimated. Low scores for the QCT measures vertebral trabecular
BMD, femoral neck cortical thickness, and femoral neck trabecular
BMD have been associated with increased risk of fractures in both
men and women.15
Two studies have used skeletal imaging techniques to compare
bone disease in MGUS patients to matched controls.16,17 In a study
on 50 MGUS patients, compared with 100 controls, MGUS
patients were found to have decreased BMD at the total femur, but
no differences were found at other sites. High-resolution peripheral
QCT (HRpQCT) imaging showed an overall increase in bone size,
diminished cortical thickness, increased endocortical area of the
distal radius, higher cortical porosity, and reduced bone strength in
MGUS patients.16,17 In addition to this, bone metabolism in MGUS
may be altered, although studies on bone markers have shown
inconclusive results.17-21
In summary, these data indicate that MGUS patients have an
increased risk of fractures and altered bone microstructure.
However, it is uncertain whether the risk of fractures is a result of
loss of BMD, or due to other factors affecting bone strength. MGUS
is an asymptomatic condition and prior studies are mostly limited to
individuals that have incidentally been diagnosed with MGUS. This
limits the generalizability of previous studies due to the underlying
conditions or symptoms that led to a diagnosis of MGUS. Therefore,
an MGUS study using patients from a screening program is ideal to
avoid this.
To better understand the underlying mechanisms of bone disease in
MGUS, we conducted a screening for MGUS in a population-based
cohort of 5764 elderly Icelandic men and women, in which 300
individuals had MGUS and 275 individuals had LC-MGUS, and
measured BMD and bone volume in all participants. Furthermore,
we collected information on fractures during a follow-up of almost
7 years. Because women have a higher risk of osteoporosis and
fractures due to hormonal features,22 we assessed men and women
separately.
Methods
AGES Reykjavik
The Age, Gene/Environment Susceptibility–Reykjavik Study (AGES-
RS)23,24 is a continuation of the Reykjavik Study, a population-based
cohort study that started in 1967. In the Reykjavik Study, men and
women born in 1907 to 1935 and living in the Reykjavik area were
invited to participate, and 19 381 attended (63%). The AGES-RS
Study started in 2002 when 8030 randomly selected individuals of
the 11 549 surviving participants from the Reykjavik Study were
invited to take part again, and 5764 enrolled (72%). In 3 clinic visits,
extensive data were collected and various measurements per-
formed, including anthropometry and QCT measurements. Partic-
ipants were asked to bring all medications used in the 2 weeks
leading up to the first visit representing current medication, and
drugs affecting bone metabolism were identified (tibolone, antiep-
ileptics, systemic glucocorticosteroids, raloxifene, calcitonin, and
bisphosphonates).
Bone measurements and fractures
The radiological measurements have been described in detail
previously.22 In brief, QCT measurements were performed in the
lumbar spine and the left hip with a 4-row detector CT system
(Sensation; Siemens Medical Systems, Erlangen Germany). A
calibration phantom was used to calibrate CT Hounsfield units to
equivalent bone mineral concentrations. In the lumbar spine, a
helical study of the L1 and L2 vertebrae was performed, and in the
hip the helical study included the proximal femur from a point 1 cm
superior to the acetabulum to a point 3 to 5 mm inferior to tro-
chanter minor.
CT images were transferred from the CT scanner to a network of
computer workstations equipped with the Linux operating system
(Red Hat Version 7.2) and the AVS5 visualization program (AVS,
Waltham, MA). Images were processed to extract measures of
volumetric BMD and bone size from scans of the spine and hip
using semiautomatic analysis techniques. This involved calibra-
tion of the images and segmentation procedures to determine
trabecular, cortical, and integral regions of interest in the L1 and
L2 vertebrae and the proximal femur. For each region, trabecular,
cortical, and integral volumetric BMD (grams per cubed centime-
ters) was obtained.
Reasons for exclusion from QCT measurements were metal
implants at the scanned area, weight over 150 kg, and inability to
lie supine. A total of 447 spine measurements were unavailable, 31
in the MGUS group and 35 in the LC-MGUS group. Furthermore,
912 hip measurements were not available, 66 for MGUS and
60 for LC-MGUS. Individuals with data missing for both spine and
hip (a total of 420, including 31 MGUS and 32 LC-MGUS)
were excluded. Thus, in the final analysis, a total of 5278 spine
measurements (92%of total, 269 for MGUS and 240 for LC-MGUS)
and 4813 hip measurements (84% of total, 234 for MGUS and 215
for LC-MGUS) were used.
Fracture data were ascertained from the Reykjavik Study fracture
registry, which is verified by medical and radiological records.25
Since the late 1960s, all patients with fractures diagnosed on an
outpatient basis in Reykjavik were referred to the region’s only
outpatient trauma clinic based at the Landspitali University Hospital.
Hospital records for all participants from Landspitali University
Hospital, and Akureyri Hospital, the largest hospital outside Reykjavik,
were accessed using the participants’ personal identification
numbers. All fractures were recorded from the individuals’ enrollment
into the study until 31 December 2011, with a mean follow-up time of
6.9 years (median, 8.2 years). In the fracture analysis, individuals were
censored after first fracture.
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MGUS and LC-MGUS diagnosis
Blood was drawn from each participant at the first clinic visit in the
AGES-RS study. To identify individuals with MGUS and LC-MGUS,
serum samples were subjected to conventional agarose-gel serum
electrophoresis (SPEP; Helena Laboratories, Beaumont, TX). In
samples with M-proteins present, immunofixation electrophoresis
was performed (SPIFE 3000; Helena Laboratories, Beaumont, TX).
Finally, the serum free light chain (FLC) assay was performed on a
SPAPLUS automated analyzer for special protein analysis using
Freelite reagents (Freelite; The Binding Site Ltd, Birmingham,
United Kingdom). Two individuals, blinded to details concerning the
samples being tested, did all testing and interpretations. MGUS
was defined as having M-protein present on SPEP and an M-protein
concentration of ,30 g/L. LC-MGUS was defined as having no
M-protein visible on SPEP, having a pathological FLC ratio (,0.26
or.1.65) on FLC analysis as well as an increased concentration of
the involved light chain (f-k. 19.4 mg/L, f-l . 26.3 mg/L).1 A total
of 39 individuals were excluded from analysis due to previous
lymphoproliferative disease at baseline (21), missing blood sample
(16), missing consent form (1), or M-protein concentration above
the limit for MGUS (1).
The study was approved by the Icelandic National Bioethics
Committee (VSN 00-063), the Icelandic Data Protection Authority,
and the US National Institute on Aging Institutional Review Board.
Statistical analysis
Mean values of QCT measurements were calculated for 3 groups:
MGUS, LC-MGUS, and those without MGUS. Analysis of variance
(ANOVA) was used to determine whether there was a significant
difference between the means. When ANOVA showed a significant
result, the Tukey honest significance difference test (Tukey HSD)
was used to define between which groups there was a significant
difference. Results were adjusted for age and sex, and in a separate
analysis for age, sex, height, and weight.
Cox proportional hazard models were used to compare risk of
fractures in individuals with MGUS, LC-MGUS, and those without
MGUS. Time at risk was defined as time from enrollment in AGES-RS
until first fracture, progression to MM, death, or end of follow-up. Cox
proportional hazard models were also used to examine whether
fractures in individuals with MGUS were a risk factor for progression
to MM. Hazard ratios (HRs) and 95% confidence intervals (CIs) were
estimated overall and separately for men and women, adjusted for
age and sex. Results were considered significant at P , .05. All
statistical analysis was performed in R version 3.2.2.26
Due to the unexpectedly high prevalence of LC-MGUS in our study
cohort (4.8%) with a great k dominance (96%), we performed
further analysis. We did additional assessments using different
cutoffs for LC-MGUS and defined LC-MGUS using the 97.5th
percentile of the log-transformed k and l values (that resembled
normal distribution).
Results
Of the 5725 included participants, 2419 were men and 3306
women, with a median age of 76 years. Among these, 300
individuals with MGUS (159 men and 141 women) and 275
individuals with LC-MGUS (156 men and 119 women) were
identified. The median age was higher for MGUS (78 years) and
LC-MGUS (80 years), than for individuals without MGUS (76 years).
Furthermore, there was a male dominance in the MGUS and LC-
MGUS groups, as opposed to a female dominance in the group
without MGUS. Individuals with MGUS and LC-MGUS had a
significantly higher mean height than the other groups. The proportion
of smokers and of individuals taking osteoporosis medications or
glucocorticoids was similar for the groups (Table 1).
QCT measurements
A total of 5305 individuals were included in the bone analysis,
including 269 individuals with MGUS (148 men and 121 women)
and 243 individuals with LC-MGUS (141 men and 102 women).
No difference was found in integral BMD between subjects with
MGUS, LC-MGUS, and others at the spine (P5 .34), femoral neck
(P 5 .72), trochanter region (P 5 .35), or total hip (P5 .30; Tables
2-4). Similarly, no difference was found in trabecular or cortical
BMD (Tables 2-4).
Volumetric measurements showed that individuals with MGUS had a
statistically significant increase in vertebral body cross-sectional area
for both L1 (P, .001) and L2 (P, .001), as well as mean vertebral
volume of L1/L2 compared with those without MGUS (P , .001;
Table 2). In the femoral neck area, both cortical (P , .001) and
integral volume (P , .001; Table 3) was significantly increased in
MGUS compared with others. In the trochanter area, a significant
difference was found in integral volume (P , .001; Table 3). In total
hip, a significant increase was found in cortical (P, .001), trabecular
(P , .001), and integral volume (P , .001; Table 4) in MGUS
compared with those without MGUS. Furthermore, a significant
difference was found in integral bone volume in total hip in MGUS
men, compared with other men (P 5 .046).
Correspondingly, for LC-MGUS, a significant increase in bone volume
was found at vertebral body cross-sectional area for L1 (P, .001) and
L2 (P , .001), and mean vertebral volume of L1/L2 compared with
others (P , .001; Table 2). In the femoral neck and trochanter area,
integral volume was significantly increased in LC-MGUS compared
with others (P 5 .02 and P , .001; Table 3). In total hip, a significant
increase was found in cortical (P , .001), trabecular (P , .001), and
integral volume (P , .001; Table 4) in LC-MGUS compared with
others. Women with LC-MGUS had a significant increase in cortical
volume in femoral neck (P 5 .015) and total hip (P 5 .006).
Furthermore, in women with LC-MGUS, a significant decrease in
integral BMD was found at the trochanter area (P5 .02) and total hip
(0.026) compared with other women.
Further adjustments for weight in BMD measurements, or for height
in volumetric measurements, did not change the results (data not
shown).
Fractures
All patients were included in the fracture analysis. A total of 1334
fractures were recorded after a median follow-up time of 6.9 years
(range, 0-11.3 years; Table 5). A total of 74 fractures were in the
MGUS group (34 in men and 40 in women), and 62 in the LC-MGUS
group (19 in men and 43 in women). Overall, the risk of fractures was
not significantly increased in individuals with MGUS (HR, 1.19; 95%
CI, 0.94-1.50) or LC-MGUS (HR, 1.05; 95% CI, 0.82-1.36) as
compared with others. Men with MGUS had a significantly increased
risk of fractures, compared with other men (HR, 1.49; 95% CI, 1.03-
2.08), whereas no increased risk of fractures was found in women
with MGUS compared with women without MGUS (HR, 1.02; 95%
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CI, 0.74-1.40). A total of 18 MGUS patients progressed to MM in the
follow-up time, of those, 4 had a fracture before progression (2 men
and 2 women). MGUS patients with fractures were not at increased
risk of progression to MM compared with MGUS patients without
fractures (HR, 0.77; 95% CI, 0.24-2.47). Further analysis comparing
individuals with MGUS with fractures to those with MGUS who did
not develop fractures showed no significant difference in known risk
factors for progression to MM (M-protein concentration, M-protein
isotype, or FLC ratio , 0.26 or . 1.65; data not shown).
Furthermore, MGUS patients who developed fractures in the
follow-up time had a decreased BMD at the spine (P , .001),
femoral neck (P 5 .005), trochanter (P , .001), and total hip
(P , .001), compared with other individuals with MGUS.
Sensitivity analysis
As previously described, we performed additional analyses using
different cutoffs for LC-MGUS, where we defined LC-MGUS
using the 97.5th percentile of the log-transformed k and l values.
Using 40.0 mg/L of the light chain involved as a cutoff resulted in 52
LC-MGUS cases (0.9%), 41 k and 11 l. Results from the sensitivity
analysis confirmed previous findings, except that the significant
Table 1. Characteristics of the study participants
No MGUS MGUS LC-MGUS ANOVA/x2 test
No. of patients 5150 300 275
Median age (range), y 76 (66-98) 78 (67-93) 79 (66-97) P < .001
Sex, no. male/female 2104/3046 159/141 156/119 P < .001
Mean weight, kg 75.3 75.4 76.4 P 5 .50
Mean height, cm 166.7 167.7 168.0 P 5 .01
Current smoker (%) 618 (12.4) 32 (11.2) 29 (10.9) P 5 .66
Osteoporosis drugs (%)* 156 (3.0) 6 (2.0) 6 (2.2) P 5 .44
Glucocorticoids (%) 143 (3.0) 13 (4.7) 10 (3.9) P 5 .25
P values shown in bold represent P , .05.
*Bisphosphonates, calcitonin, and lasofoxifene.
Table 2. Results from QCT measurements: lumbar spine
Lumbar spine
Mean measurements
ANOVA* Tukey HSD*No MGUS MGUS LC-MGUS
Average L1 and L2 integral BMD, mg/cm3 Men 0.206 0.206 0.205 P 5 .989 NS
Women 0.185 0.186 0.176 P 5 .056 NS
All 0.194 0.197 0.193 P 5 .343 NS
Average L1 and L2 trabecular BMD, mg/cm3 Men 0.0867 0.0883 0.0831 P 5 .387 NS
Women 0.0730 0.0762 0.0661 P 5 .0366 PMGUS 5 .492
PLC-MGUS 5 .610
All 0.0787 0.0828 0.0760 P 5 .041 PMGUS 5 .097
PLC-MGUS 5 .402
Vertebral body cross-sectional area L1, cm2 Men 13.38 13.47 13.23 P 5 .580 NS
Women 10.28 10.38 10.40 P 5 .688 NS
All 11.56 12.08 12.05 P < .001 PMGUS < .001
PLC-MGUS < .001
Vertebral body cross-sectional area L2, cm2 Men 12.21 12.42 12.15 P 5 .429 NS
Women 9.27 9.42 9.20 P 5 .593 NS
All 10.49 11.07 10.92 P < .001 PMGUS < .001
PLC-MGUS 5 .001
Mean volume, cm3 Men 45.96 46.37 45.92 P 5 .740 NS
Women 35.13 35.43 35.23 P 5 .804 NS
All 39.61 41.45 41.46 P < .001 PMGUS < .001
PLC-MGUS < .001
P values shown in bold represent P , .05.
NS, not significant.
*Adjusted for age and sex.
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findings of lower BMD in trochanter and total hip for LC-MGUS
women were no longer significant (data not shown).
Discussion
In this screened population-based study, including .5300 individ-
uals, we found that individuals with MGUS did not have decreased
BMD, however, interestingly, bone volume was increased in lumbar
spine, femoral neck, trochanter, and total hip. This increase in bone
volume was more pronounced in men with MGUS, who also had a
significantly increased risk of fractures. Our findings suggest an
effect of MGUS on bone metabolism that does not affect BMD, but
which increases our understanding of bone disease in MM.
We found no difference in BMD between MGUS, LC-MGUS, and
others at any site, in fact, our results show consistently that there
seems to be no difference between the groups, with comparable
mean values for all groups. These results are in accordance with the
findings of Ng et al, wherein DXA measurements on 50 MGUS
patients, compared with 100 controls, showed no significant
difference in areal BMD at lumbar spine, femur neck, or total radius,
although they did find a significant difference in areal BMD at total
Table 3. Results from QCT measurements: femoral neck and trochanter
Femoral neck and trochanter
Mean measurements
ANOVA* Tukey HSD*No MGUS MGUS LC-MGUS
Femoral neck
Integral BMD, mg/cm3 Men 0.254 0.255 0.253 P 5 .907 NS
Women 0.245 0.242 0.236 P 5 .188 NS
All 0.249 0.249 0.246 P 5 .716 NS
Trabecular BMD, mg/cm3 Men 0.0397 0.0406 0.0366 P 5 .695 NS
Women 0.0234 0.0221 0.0169 P 5 .348 NS
All 0.0303 0.0324 0.0287 P 5 .646 NS
Cortical BMD, mg/cm3 Men 0.543 0.546 0.544 P 5 .648 NS
Women 0.533 0.533 0.532 P 5 .950 NS
All 0.537 0.541 0.539 P 5 .437 NS
Integral volume, cm3 Men 20.22 20.87 19.94 P 5 .126 NS
Women 14.81 14.57 14.38 P 5 .263 NS
All 17.10 18.07 17.72 P < .001 PMGUS < .001
PLC-MGUS 5 .02
Cortical volume, cm3 Men 7.79 8.03 7.72 P 5 .191 NS
Women 5.74 5.59 5.39 P 5 .010 PMGUS 5 .388
PLC-MGUS 5 .0153
All 6.61 6.95 6.79 P < .001 PMGUS < .001
PLC-MGUS 5 .136
Trochanter
Integral BMD, mg/cm3 Men 0.250 0.252 0.244 P 5 .350 NS
Women 0.227 0.224 0.214 P 5 .0236 PMGUS 5 .774
PLC-MGUS 5 .020
All 0.237 0.239 0.257 P 5 .257 NS
Trabecular BMD, mg/cm3 Men 0.0764 0.0771 0.0721 P 5 .382 NS
Women 0.0570 0.0568 0.0494 P 5 .110 NS
All 0.0652 0.0681 0.0630 P 5 .280 NS
Cortical BMD, mg/cm3 Men 0.546 0.549 0.544 P 5 .645 NS
Women 0.522 0.520 0.517 P 5 .429 NS
All 0.532 0.536 0.533 P 5 .327 NS
Integral volume, cm3 Men 89.04 91.69 88.32 P 5 .107 NS
Women 64.76 63.85 63.45 P 5 .301 NS
All 75.05 79.32 78.38 P < .001 PMGUS < .001
PLC-MGUS < .001
P values shown in bold represent P , .05.
Abbreviations are explained in Table 2.
*Adjusted for age and sex.
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femur.16 In a previous large screening study, a 20% increased risk
for a diagnosis of osteoporosis was found in individuals with
MGUS.6 This is contradictory to our results, but might be explained
by the increased surveillance of individuals with MGUS, thus
leading to more investigations (DXA scans) and diagnoses of
osteoporosis, and not necessarily indicating a lower BMD in the
group. Results from previous studies on patients with MM have
shown decreased BMD compared with age- and sex-matched
controls,27,28 although this decrease does not seem to correlate
with the extent of osteolytic lesions,29 and might therefore not
reflect the extent of the disease.
We observed an increase in bone volume at lumbar spine, femoral
neck, trochanter, and total hip in MGUS and LC-MGUS, compared
with those without MGUS. This is consistent with 2 studies from the
Mayo Clinic using skeletal imaging, where HRpQCT measurements
of the radius showed increased bone size, increased cortical
porosity, and decreased cortical thickness.16,17 This increase in
bone size might reflect a process similar to periosteal bone
apposition, which is known to occur with increasing age, where
there is a loss of trabecular bone, and in response to that a
periosteal renewal of bone cells leading to an increase in cross-
sectional area of bone. This is believed to contribute to maintaining
bone strength in age-related bone loss.22,30 Furthermore, some
studies have shown elevated levels of certain bone markers in
MGUS, indicating changed metabolism in MGUS.16,18-21 Thus,
there seems to be an alteration of both bone structure and
metabolism in MGUS, although the association between these
changes and progression to MM or bone disease in MM are still
unclear. To our knowledge, no changes in bone volume have been
reported in MM.
When the risk of fractures was analyzed for men and women
together, no significant increase in risk of fractures was detected in
individuals with MGUS. Results from previous studies, with more
individuals with MGUS and longer follow-up, have shown an
increased risk of fractures in MGUS, however, all were based on
clinical cohorts and thus subject to bias.4,5,31 Interestingly, we
found that men with MGUS had a 1.5-fold increased risk of
fractures compared with other men. This is consistent with earlier
findings that have shown a higher relative risk of fractures in men
with MGUS than in women,4 and that men with MGUS have an
unexpected high prevalence of vertebral fractures.32 In post-
menopausal women, the generally enhanced rate of bone loss
may mask the effect of MGUS on bone metabolism.22 Further
analysis on the MGUS individuals who developed fractures showed
Table 4. Results from QCT measurements: total hip
Total hip
Mean measurements
ANOVA* Tukey HSD*No MGUS MGUS LC-MGUS
Integral BMD, mg/cm3 Men 0.249 0.250 0.244 P 5 .467 NS
Women 0.228 0.226 0.216 P 5 .031 PMGUS 5 .811
PLC-MGUS 5 .026
All 0.237 0.239 0.233 P 5 .301 NS
Trabecular BMD, mg/cm3 Men 0.0732 0.0739 0.0693 P 5 .437 NS
Women 0.0543 0.0541 0.0471 P 5 .122 NS
All 0.0623 0.0651 0.0604 P 5 .314 NS
Cortical BMD, mg/cm3 Men 0.532 0.535 0.530 P 5 .646 NS
Women 0.513 0.511 0.508 P 5 .467 NS
All 0.521 0.524 0.521 P 5 .459 NS
Integral volume, cm3 Men 119.44 123.59 118.58 P 5 .026 PMGUS 5 .052
PLC-MGUS 5 .882
Women 85.70 84.65 83.75 P 5 .331 NS
All 100.00 106.28 104.65 P < .001 PMGUS < .001
PLC-MGUS < .001
Trabecular volume, cm3 Men 42.41 43.98 41.99 P 5 .125 NS
Women 25.86 25.68 25.22 P 5 .548 NS
All 32.87 35.85 35.28 P < .001 PMGUS < .001
PLC-MGUS < .001
Cortical volume, cm3 Men 42.49 43.78 41.62 P 5 .113 NS
Women 29.95 29.27 27.91 P 5 .005 PMGUS 5 .497
PLC-MGUS 5 .006
All 35.27 37.33 36.14 P < .001 PMGUS < .001
PLC-MGUS 5 .200
P values shown in bold represent nnn.
Abbreviations are explained in Table 2.
*Adjusted for age and sex
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that they had a lower BMD than individuals with MGUS who did not
develop fractures, indicating that processes known from osteopo-
rosis play a role in fractures in this group, just like in the general
population.
The main strength of our study, as compared with previous studies on
bone disease in MGUS, is that our study population is detected
through screening and is population based, and both patients and their
health care providers were blinded to their MGUS during the study.
Furthermore, the AGES-RS population is well described, and includes
extensive information on individual factors such as height, weight, as
well as current medication affecting bone metabolism.33 Another
strength of our study is the use of QCT measurements that have
previously been shown to correlate well with DXA measurements as
well as subsequent risk of fracture.15,34 Furthermore, QCT measure-
ments as opposed to DXA are not confounded by skeletal size and
provide measurements from trabecular and cortical bone separately.
A limitation to our study, as with other MGUS studies, is that we do
not know when individuals developed MGUS, thus, some individ-
uals might not have had the condition for a long time. Assuming that
bone disease develops gradually, we might not find a difference in
BMD between the groups because of the limited duration of
MGUS. Another limitation is that using QCT, despite its benefits
mentioned earlier in text, does not allow for comparison with
other studies on bone disease in MGUS that have mostly used
DXA. The bone analysis used in our study did not have suffi-
cient resolution to study microstructural changes in bone, like
HRpQCT, which has been used in other studies. Furthermore,
we did not have bone marrow samples from our participants, and
can therefore not rule out that the individuals that are in the
MGUS group might have smoldering myeloma or MM despite
the low M-protein concentration. Another limitation is that the
Icelandic AGES-RS population is an ethnically homogenous
population, thus, the results may not be applicable to individuals
of another ethnicity than white. Moreover, the AGES population
is elderly, with a median age of 76 years, therefore, results may
be different for younger MGUS patients. Another consideration
is that lack of power in the fracture analysis might explain why we
do not find an increased risk of fractures for the whole MGUS
group, however, the normal BMD speaks against increased
fracture risk.
As for clinical considerations, our results do not support measuring
BMD in MGUS patients to screen for osteopenia/osteoporosis, as
our study shows that they do not have a lower BMD than others in the
same age group. However, our results suggest that individuals with
MGUS have an altered bone metabolism and the men with MGUS
have an increased risk of fractures. Our findings are in line with the
results of a recent meta-analysis of bone disease in MGUS, where
the authors concluded that there was evidence of increased fracture
risk in MGUS, although BMD did not seem to be significantly
altered.35 Therefore, further studies are needed to determine how
MGUS patients with increased risk of fractures can be identified and
how and if they should be treated prophylactically. Treatment with
bisphosphonates has been investigated to some extent in MGUS,
and has been shown to increase BMD.36,37 However, the effect of
bisphosphonates on future skeletal-related events and bone structure
in MGUS remains uncertain.
In conclusion, our large population-based study suggests that
BMD is not decreased in individuals with MGUS as compared
with others. Furthermore, we found that individuals with MGUS
had an increased bone volume at lumbar spine, femoral neck,
trochanter, and total hip. The increased bone volume was more
marked in men with MGUS, who were at increased risk of
fractures. This suggests an effect of MGUS on bone metabolism
in men that is not noted in women, possibly as a result of other
stronger risk factors in postmenopausal women. Our results
could represent compensatory bone metabolism in MGUS due
to ongoing bone marrow pathology, driven by abnormal plasma
cells, or other processes that are currently unclear, and warrant
further studies on bone metabolism and/or structure in MGUS
and MM.
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